GLP-1 Research Peptides: The Complete 2026 Guide — Semaglutide, Tirzepatide, Retatrutide & Beyond

The GLP-1 receptor agonist class represents the most actively researched peptide category in 2026. What began with liraglutide's 97% GLP-1 homology has evolved into a second generation of dual agonists and a third generation of triple agonists with metabolic effects exceeding anything previously observed in pharmacological research.

First Generation: Single GLP-1 Agonists

Liraglutide

Liraglutide's 97% homology to native GLP-1 and C16 fatty acid modification made it the first practical once-daily GLP-1 analogue. The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events — establishing GLP-1's cardiovascular benefits as a class effect. Half-life approximately 13 hours.

Semaglutide

Semaglutide's C18 fatty diacid chain enables albumin binding that extends half-life to 165-184 hours — enabling once-weekly dosing. STEP 1 demonstrated 14.9% mean body weight reduction over 68 weeks. Semaglutide became the reference standard against which all subsequent GLP-1 class compounds are benchmarked. Molecular weight 4113.6 Da.

Dulaglutide

The IgG4-Fc fusion architecture of dulaglutide creates a large molecule (~59,700 Da) with exceptional stability and a 5-day half-life. The REWIND cardiovascular outcomes trial showed 12% MACE reduction.

Second Generation: Dual Agonists

Tirzepatide (GLP-1 + GIP)

Tirzepatide's simultaneous activation of both GLP-1 and GIP receptors produces synergistic effects exceeding either agonist alone. SURPASS-2 showed tirzepatide 15mg outperformed semaglutide 1mg on both HbA1c reduction (2.37% vs 1.86%) and weight loss (11.2kg vs 6.2kg). SURMOUNT-1 documented 20.9% mean weight reduction at maximum dose — then a record. Molecular weight 4813.5 Da.

Mazdutide (IBI362) — GLP-1 + Glucagon

Mazdutide's glucagon co-agonism adds thermogenic effects that pure GLP-1 agonists lack. Phase 3 trials in China are ongoing, with particular interest in NASH applications given glucagon's hepatic fat-reducing effects.

Survodutide (BI 456906) — Glucagon-biased dual agonist

Survodutide's glucagon-heavy receptor bias makes it the leading investigational compound for NAFLD/NASH research. Phase 2b data showed liver fat reductions of up to 60% over 24 weeks.

Cagrilintide (Amylin analogue) + Cagrisema

Cagrilintide operates through amylin receptors in the area postrema — an anatomically distinct pathway from hypothalamic GLP-1 signaling. Combined with semaglutide as Cagrisema, REDEFINE Phase 3 demonstrated 22.7% mean weight reduction — superior to either compound alone and consistent with the complementary non-redundant mechanism.

Third Generation: Triple Agonist

Retatrutide (GLP-1 + GIP + Glucagon)

As covered extensively in recent TRIUMPH-4 results, retatrutide's three-receptor mechanism has achieved 28.7% average weight loss in Phase 3 — the highest pharmacological weight reduction recorded. Seven additional Phase 3 readouts expected in 2026. FDA approval projected 2027.

The Oral Frontier

Orforglipron

A non-peptide small molecule GLP-1 receptor agonist, orforglipron's oral bioavailability bypasses the injection requirement entirely. Phase 3 results have been positive for both obesity and type 2 diabetes, and Eli Lilly has submitted to the FDA for review. Approval expected 2026.

Research Applications

For researchers, the GLP-1 family offers unparalleled tools for studying metabolic pathways:

• Insulin secretion mechanics (glucose-dependent)
• Gastric emptying regulation
• Hypothalamic appetite signaling
• Cardiovascular risk factor modulation
• Hepatic fat metabolism (dual/triple agonists)
• Adipose tissue biology

The availability of compounds spanning single, dual, and triple receptor agonism allows comparative research that has been scientifically transformative.

*All products for laboratory research purposes only. Not for human consumption.*